Results of the PFT in the 27 never-smoking patients with pSS compared to predicted values. Clinically significant reversibility was defined as FEV1 improvement > 12% and > 200 ml. Values are mean ± SD or % with abnormal findings unless otherwise specified.
| PFT Results | Never-smoking Patients with pSS, n = 27 | Predicted Values, Absolute No. | p Values, Never-smoking pSS vs Predicted | |
|---|---|---|---|---|
| Absolute No. | % of Predicted | |||
| VC, l | 3.5 ± 0.9 | 96 ± 15 | 3.8 ± 1.0 | 0.060 |
| TLC, l | 5.8 ± 1.2 | 102 ± 11 | 5.6 ± 0.9 | 0.300 |
| RV, l | 2.2 ± 0.5 | 121 ± 19 | 1.9 ± 0.4 | 0.0001 |
| RV/TLC ratio | 0.39 ± 0.1 | 119 ± 20 | 0.34 ± 0.1 | 0.0001 |
| FEV1, l | 2.5 ± 0.6 | 88 ± 14 | 2.9 ± 0.8 | 0.0001 |
| FEV1/VC ratio | 0.72 ± 0.08 | 94 ± 8 | 0.76 ± 0.03 | 0.001 |
| DLCO, mmol/min kPa | 7.1 ± 1.9 | 102 ± 11 | 7.6 ± 1.9 | 0.065 |
| DLCO, < 80% of predicted, n (%) | 5/18 | NA | NA | |
| COPD | 30 | NA | NA | |
| Mild | 75 | NA | NA | |
| Moderate | 25 | NA | NA | |
| Severe | 0 | NA | NA | |
| Clinically significant reversibility, n/% | 0/0 | NA | NA | |
PFT: pulmonary function tests; pSS: primary Sjögren syndrome; FEV1: forced expiratory volume in 1 s; VC: vital capacity; TLC: total lung capacity; RV: residual volume; COPD: chronic obstructive pulmonary disease; NA: not assessed.